Role of aerosolized colistin methanesulfonate therapy for extensively-drug-resistant Acinetobacter baumannii complex pneumonia and airway colonization

Journal of Microbiology, Immunology and Infection

Volumn 49, Issue 4, 2016, Pages 523-530

  Hsieh, Tai Chin ^a,b   Chen, Fu Lun ^a,b   Ou, Tsong Yih ^a,b   Jean, Shio Shin ^a   Lee, Wen Sen ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Acinetobacter baumannii; aerosolized; colistin; colistin methanesulfonate; pneumonia

Indexed keywords

CARBAPENEM; CEPHALOSPORIN; COLISTIMETHATE; PREDNISOLONE; SULBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT; COLISTIN; COLISTINMETHANESULFONIC ACID;

ACINETOBACTER INFECTION; ACUTE KIDNEY FAILURE; ADD ON THERAPY; AEROSOL; AGED; AIRWAY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; BRONCHOSPASM; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; EXTENSIVELY DRUG RESISTANT ACINETOBACTER BAUMANNII COMPLEX PNEUMONIA; FEMALE; HOSPITAL MORTALITY; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MECHANICAL VENTILATOR; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; RETROSPECTIVE STUDY; STEROID THERAPY; VERY ELDERLY; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; MALE; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84923923596     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2014.08.009     Document Type: Article

References (28)

1. 1 Jawad, A., Heritage, J., Snelling, A.M., Gascoyne-Binzi, D.M., Hawkey, P.M., Influence of relative humidity and suspending menstrua on survival of Acinetobacter spp. on dry surfaces. J Clin Microbiol 34 (1996), 2881–2887.
2. 2 Fournier, P.E., Richet, H., The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 42 (2006), 692–699.
3. 3 Marchaim, D., Navon-Venezia, S., Schwartz, D., Tarabeia, J., Fefer, I., Schwaber, M.J., et al. Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii. J Clin Microbiol 45 (2007), 1551–1555.
4. 4 Manikal, V.M., Landman, D., Saurina, G., Oydna, E., Lal, H., Quale, J., Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 31 (2000), 101–106.
5. 5 Linden, P.K., Paterson, D.L., Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 43 (2006), 89–94.
6. 6 Li, J., Coulthard, K., Milne, R., Nation, R.L., Conway, S., Peckham, D., et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 52 (2003), 987–992.
7. 7 Hartzell, J.D., Neff, R., Ake, J., Howard, R., Olson, S., Paolino, K., et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 13 (2009), 1724–1728.
8. 8 Lu, Q., Girardi, C., Zhang, M., Bouhemad, B., Louchahi, K., Petitjean, O., et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med 36 (2010), 1147–1155.
9. 9 Kang, C.H., Tsai, C.M., Wu, T.H., Wu, H.Y., Chung, M.Y., Chen, C.C., et al. Colistin inhalation monotherapy for ventilator-associated pneumonia of Acinetobacter baumannii in prematurity. Pediatr Pulmonol 49 (2014), 381–388.
10. 10 Choi, H.K., Kim, Y.K., Kim, H.Y., Uh, Y., Inhaled colistin for treatment of pneumonia due to colistin-only-susceptible Acinetobacter baumannii. Yonsei Med J 55 (2014), 118–125.
11. 11 Khawcharoenporn, T., Pruetpongpun, N., Tiamsak, P., Rutchanawech, S., Mundy, L.M., Apisarnthanarak, A., Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob Agents 43 (2014), 378–382.
12. 12 Kuo, S.C., Lee, Y.T., Yang, S.P., Chen, C.P., Chen, T.L., Hsieh, S.L., et al. Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: a matched case–control study. Clin Microbiol Infect 18 (2012), 870–876.
13. 13 Johanson, W.G. Jr., Pierce, A.K., Sanford, J.P., Thomas, G.D., Respiratory infections with gram negative bacilli: the significance of colonization of the respiratory tract. Ann Intern Med 77 (1972), 701–706.
14. 14 Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement. Document M100–S17, 2007, CLSI, Wayne.
15. 15 European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 2.0, valid from 2012-01-01. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_2.0_120221.pdf [accessed 15.01.14].
16. 16 Liao, C.H., Kung, H.C., Hsu, G.J., Lu, P.L., Liu, Y.C., Chen, C.M., et al. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods. Int J Antimicrob Agents 32:Suppl. 3 (2008), S192–S196.
17. 17 Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18 (2012), 268–281.
18. 18 Lee, Y.T., Tsao, S.M., Hsueh, P.R., Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis 32 (2013), 1211–1220.
19. 19 Abosaif, N.Y., Tolba, Y.A., Heap, M., Russell, J., El Nahas, A.M., The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability. Am J Kidney Dis 46 (2005), 1038–1048.
20. 20 Gordon, N.C., Wareham, D.W., A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 63 (2009), 775–780.
21. 21 López-Cortés, L.E., Cisneros, J.M., Fernández-Cuenca, F., Bou, G., Tomás, M., Garnacho-Montero, J., et al. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother, 2014 http://dx.doi/10.1093/jac/dku327.
22. 22 Nation, R.L., Li, J., Colistin in the 21st century. Curr Opin Infect Dis 22 (2009), 535–543.
23. 23 Ratjen, F., Rietschel, E., Kasel, D., Schwiertz, R., Starke, K., Beier, H., et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 57 (2006), 306–311.
24. 24 Yapa, S.W.S., Li, J., Patel, K., Wilson, J.W., Dooley, M.J., George, J., et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother 58 (2014), 2570–2579.
25. 25 Yahav, D., Lador, A., Paul, M., Leibovici, L., Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 66 (2011), 1963–1971.
26. 26 Burkhardt, O., Rauch, K., Kaever, V., Hadem, J., Kielstein, J.T., Welte, T., Tigecycline possibly under dosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 34 (2009), 101–102.
27. 27 Chuang, Y.C., Sheng, W.H., Lauderdale, T.L., Li, S.Y., Wang, J.T., Chen, Y.C., et al. Molecular epidemiology, antimicrobial susceptibility and carbapenemase resistance determinants among Acinetobacter baumannii clinical isolates in Taiwan. J Microbiol Immunol Infect 47 (2014), 324–332.
28. OxA-23 from hospitals in central Taiwan. J Microbiol Immunol Infect 46 (2013), 419–424.